United States - English - NLM (National Library of Medicine)

avet pharmaceuticals inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - predialysis patients calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with posts

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - predialysis patients calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with posts

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - calcitriol 0.25ug;   - soft gelatin capsule - 0.25 mcg - active: calcitriol 0.25ug   excipient: butylated hydroxyanisole butylated hydroxytoluene coconut oil gelatin glycerol iron oxide black purified water quinoline yellow shellac sorbitol titanium dioxide - · established postmenopausal osteoporosis

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - calcitriol 0.5ug;   - soft gelatin capsule - 0.5 mcg - active: calcitriol 0.5ug   excipient: butylated hydroxyanisole butylated hydroxytoluene coconut oil gelatin glycerol iron oxide black patent blue v purified water quinoline yellow shellac sorbitol titanium dioxide - · established postmenopausal osteoporosis

Australia - English - Department of Health (Therapeutic Goods Administration)

scentia pharmaceuticals pty ltd - calcitriol -

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - calcipotriol monohydrate, betamethasone dipropionate - ointment - calcipotriol monohydrate 50 microgram(s)/gram ; betamethasone dipropionate 0.5 milligram(s) - antipsoriatics

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - calcitriol -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - calcitriol -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol -

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyro